Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $41.56 Consensus PT from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been given a consensus rating of “Moderate Buy” by the ten brokerages that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $41.5556.

A number of analysts recently weighed in on the stock. Mizuho began coverage on shares of Celldex Therapeutics in a research note on Tuesday, October 21st. They set an “outperform” rating and a $48.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, January 21st. Finally, Barclays raised their price target on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a report on Wednesday, December 17th.

Celldex Therapeutics Stock Up 2.1%

NASDAQ:CLDX opened at $25.17 on Friday. The company has a market capitalization of $1.67 billion, a PE ratio of -7.45 and a beta of 1.24. Celldex Therapeutics has a 52-week low of $14.40 and a 52-week high of $30.50. The stock’s 50 day moving average price is $26.59 and its 200 day moving average price is $25.20.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 33.22%. As a group, sell-side analysts anticipate that Celldex Therapeutics will post -2.48 EPS for the current fiscal year.

Insider Activity

In other news, insider Richard M. Wright sold 49,298 shares of the business’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $24.00, for a total value of $1,183,152.00. Following the transaction, the insider owned 20,833 shares of the company’s stock, valued at approximately $499,992. The trade was a 70.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.40% of the company’s stock.

Institutional Trading of Celldex Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CLDX. Values First Advisors Inc. purchased a new position in Celldex Therapeutics during the fourth quarter worth about $210,000. Vanguard Group Inc. raised its stake in shares of Celldex Therapeutics by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 4,027,407 shares of the biopharmaceutical company’s stock worth $109,384,000 after buying an additional 72,817 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in shares of Celldex Therapeutics by 67.2% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 32,263 shares of the biopharmaceutical company’s stock valued at $876,000 after buying an additional 12,966 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Celldex Therapeutics by 11.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 25,317 shares of the biopharmaceutical company’s stock valued at $688,000 after buying an additional 2,517 shares during the period. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in shares of Celldex Therapeutics by 31.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 46,965 shares of the biopharmaceutical company’s stock valued at $1,276,000 after buying an additional 11,182 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.